1. Azuma K, Osaki T, Kurozumi S, Kiyose M, Tsuka T, Murahata Y, et al. Anti-inflammatory effects of orally administered glucosamine oligomer in an experimental model of inflammatory bowel disease. Carbohydr Polym 2015; 115:448-456.
2. Al-Rejaie SS, Abuohashish HM, Al-Enazi MM, Al-Assaf AH, Parmar MY, Ahmed MM. Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J Gastroenterol 2013; 19:5633.
3. Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, et al. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-α, NF-κ Bp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm 2006; 2006:92642.
4. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009; 15:199-207.
5. Hongbao M, Young M, Yan Y. Cluster of Differentiation (CD). N Y Sci J 2015; 8:49-53.
6. Zola H, Swart B, Nicholson I, Aasted B, Bensussan A, Boumsell L, et al. CD molecules 2005: human cell differentiation molecules. Blood 2005; 106:3123-3126.
7. Karaca T, Şimşek N, Uslu S, Kalkan Y, Can I, Kara A, et al. The effect of royal jelly on CD3+, CD5+, CD45+ T-cell and CD68+ cell distribution in the colon of rats with acetic acid-induced colitis. Allergol Immunopathol (Madr) 2012; 40:357-361.
8. Műzes G, Molnár B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol 2012; 18:5848.
9. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116:1218.
10. Zhu J, Paul WE. Peripheral CD4+ T‐cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 2010; 238:247-262.
11. Jiang W, Su J, Zhang X, Cheng X, Zhou J, Shi R, et al. Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res 2014; 63:943-950.
12. Zhou L, Littman DR. Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol 2009; 21:146-152.
13. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21:467-476.
14. Fantini M, Monteleone G, MacDonald T. IL-21 comes of age as a regulator of effector T cells in the gut. Mucosal Immunol 2008; 1:110-115.
15. Aujla S, Kolls J. IL-22: a critical mediator in mucosal host defense. J Mol Med (Berl) 2009; 87:451-454.
16. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14:282-289.
17. Seiderer J, Brand S. IL‐22: A two‐headed cytokine in IBD? Inflamm Bowel Dis 2009; 15:473-474.
18. Yamamoto-Furusho JK, Miranda-Pérez E, Fonseca-Camarillo G, Sánchez-Muñoz F, Dominguez-Lopez A, Barreto-Zuniga R. Colonic epithelial upregulation of interleukin 22 (IL‐22) in patients with ulcerative colitis. Inflamm Bowel Dis 2010; 16:1823.
19. Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, Maloy KJ, et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010; 33:279-288.
20. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, Mckenzie B, et al. IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116:1310-1316.
21. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. Interleukin-23 drives innate and T cell–mediated intestinal inflammation. J Exp Med 2006; 203:2473-2483.
22. Karaca T, Uz YH, Demirtas S, Karaboga I, Can G. Protective effect of royal jelly in 2, 4, 6 trinitrobenzene sulfonic acid-induced colitis in rats. Iran J Basic Med Sci 2015; 18:370.
23. McCafferty DM, Sharkey KA, Wallace JL. Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol Gastrointest Liver Physiol 1994; 266:G560-G567.
24. Obermeier F, Kojouharoff G, Hans W, Scholmerich J, Gross V, Falk W. Interferon-gamma (IFN- )-and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 1999; 116:238-245.
25. Yang M, Lin HB, Gong S, Chen PY, Geng LL, Zeng YM, et al. Effect of Astragalus polysaccharides on expression of TNF-α, IL-1β and NFATc4 in a rat model of experimental colitis. Cytokine 2014; 70:81-86.
26. Kolgazi M, Uslu U, Yuksel M, 0Velioglu-Ogunc A, Ercan F, Alican I. The role of cholinergic anti-inflammatory pathway in acetic acid-induced colonic inflammation in the rat. Chem Biol Interact 2013; 205:72-80.
27. Wakuda T, Azuma K, Saimoto H, Ifuku S, Morimoto M, Arifuku I, et al. Protective effects of galacturonic acid-rich vinegar brewed from Japanese pear in a dextran sodium sulfate-induced acute colitis model. J Funct Foods 2013; 5:516-523.
28. Watanabe T, Asano N, Murray PJ, Ozato K, Tailor P, Fuss IJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008; 118:545-559.
29. Forster K, Goethel A, Chan CWT, Zanello G, Streutker C, Croitoru K. An oral CD3-specific antibody suppresses T-cell–induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology 2012; 143:1298-1307.
30. Reinecke K, Eminel S, Dierck F, Roessner W, Kersting S, Chromik AM, et al. The JNK inhibitor XG-102 protects against TNBS-induced colitis. Plos One 2012; 7(3): e30985.
31. Dasu T, Qualls JE, Tuna H, Raman C, Cohen DA, Bondada S. CD5 plays an inhibitory role in the suppressive function of murine CD4+ CD25+ T reg cells. Immunol Lett 2008; 119:103-113.
32. Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol 1999; 19:2903-2912.
33. Gulubova MV, Manolova IM, Vlaykova TI, Prodanova M, Jovchev JP. Adhesion molecules in chronic ulcerative colitis. Int J Colorectal Dis 2007; 22:581-589.
34. Vainer B, Nielsen OH, Horn T. Comparative studies of the colonic in situ expression of intercellular adhesion molecules (ICAM-1,-2, and-3), β2 integrins (LFA-1, Mac-1, and p150, 95), and PECAM-1 in ulcerative colitis and Crohn's disease. Am J Surg Pathol 2000; 24:1115-1124.
35. Wang L, Jiang X, Liu X, Qian T, Chu Y. Local immune compartments are related to the severity of dextran sodium sulphate induced colitis. Biosci Trends 2014; 8:242-247.
36. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005; 6:873-879.
37. Lu Y, Hong B, Li H, Zheng Y, Zhang M, Wang S, et al. Tumor-specific IL-9–producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci 2014; 111:2265-2270.
38. Chen J, Bruce D, Cantorna MT. Vitamin D receptor expression controls proliferation of naive CD8+ T cells and development of CD8 mediated gastrointestinal inflammation. BMC Immunol 2014; 15:6.
39. Steinhoff U, Brinkmann V, Klemm U, Aichele P, Seiler P, Brandt U, et al. Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity 1999; 11:349-358.
40. Ghavidel A, Somi MH, Ebrahimzadeh ZA, Halimi M, Tabrizi A. CD4+ and CD8+ T cell count in colonic mucosa of patients with IBD and IBS. J Am Sci 2013; 9(9s).
41. Funderburg NT, Stubblefield Park SR, Sung HC, Hardy G, Clagett B, Ignatz‐Hoover J, et al. Circulating CD4+ and CD8+ T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 2013; 140:87-97.
42. Liu D, Zhao H, Zhao N, Lu C, Lu A. Effect of Bawei Xilei powder on CD3, CD4, CD8 T-lymphocytes of rats with ulcerative colitis. Zhongguo Zhong Yao Za Zhi 2008; 33:1301-1304.
43. Saunders A, Johnson P. Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase, CD45. Cell Signal 2010; 22:339-348.
44. Tobisawa Y, Imai Y, Fukuda M, Kawashima H. Sulfation of colonic mucins by N-acetylglucosamine 6-O-sulfotransferase-2 and its protective function in experimental colitis in mice. J Biol Chem 2010; 285:6750-6760.
45. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448:480-483.
46. Carvalho AT, Souza H, Carneiro AJ, Castelo-Branco M, Madi K, Schanaider A, et al. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. World J Gastroenterol 2007; 13:2166.
47. Zhang M, Qiu X, Zhang H, Yang X, Hong N, Yang Y, et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. Plos One 2014; 9:e109146.
48. Yao J, Wei C, Wang JY, Zhang R, Li YX, Wang L-S. Effect of resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice. World J Gastroenterol 2015; 21:6572-6581.
49. He Y, Lin LJ, Zheng CQ, Jin Y, Lin Y. Cytokine expression and the role of Thl7 cells in mice colitis. Hepatogastro-enterology 2012; 59:1809-1813.
50. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bow Dis 2011; 17:831-848.
51. Rutz S, Eidenschenk C, Ouyang W. IL‐22, not simply a Th17 cytokine. Immunol Rev 2013; 252:116-132.
52. Leung J, Davenport M, Wolff M, Wiens K, Abidi W, Poles M, et al. IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 2014; 7:124-133.
53. Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY, Sun C, et al. Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J Gastroenterol 2013; 19:2638-2649.
54. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23–IL-17 immune pathway. Trends Immunol 2006; 27:17-23.
55. Liu Z, Yadav PK, Xu X, Su J, Chen C, Tang M, et al. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. J Leukoc Biol 2011; 89:597–606.